Physician profile
Antoine Dipsia
NPI 1013093558
$20,794.17
in general payments reported to CMS, 2019-2025
38 companies · $5,008 in 2025
The $5,008 reported for 2025 was more than what 98% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,087 · 2020: $1,679 · 2021: $2,517 · 2022: $2,860 · 2023: $3,301 · 2024: $3,344 · 2025: $5,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,652.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,095.18 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,990.42 | 2019-2025 | Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $1,958.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $1,946.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,762.30 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,263.54 | 2020-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Amgen INC. | $917.00 | 2023-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $887.61 | 2019-2024 | Spravato |
| Abbvie INC. | $664.68 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $657.95 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Genzyme Corporation | $637.41 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $592.14 | 2022-2025 | Dupixent |
| Idorsia Pharmaceuticals US INC | $525.31 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $519.89 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $470.92 | 2021-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $403.69 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $318.03 | 2024-2025 | Zenpep |
| Dexcom, INC. | $267.19 | 2024-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Verona Pharma, INC. | $225.59 | 2025 | Ohtuvayre |
| Scilex Pharmaceuticals INC. | $216.74 | 2021-2025 | Ztlido |
| Redhill Biopharma INC. | $207.87 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Biohaven Pharmaceutical Holding Company Ltd. | $197.45 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $182.28 | 2021-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $135.94 | 2019-2021 | |
| Corcept Therapeutics | $122.83 | 2025 | Korlym |
| Gilead Sciences, INC. | $113.07 | 2025 | Descovy |
| Kowa Pharmaceuticals America, INC. | $109.02 | 2025 | Zoryve |
| Radius Health, INC. | $104.01 | 2020 | |
| Abbott Laboratories | $75.30 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.37 | 2019 | |
| Electromed, INC. | $28.42 | 2025 | Smartvest |
| Phathom Pharmaceuticals, INC. | $20.89 | 2024 | Voquezna |
| Averitas Pharma INC. | $20.41 | 2023 | Qutenza |
| Sanofi Pasteur INC. | $18.24 | 2019 | |
| Circassia INC. | $17.96 | 2019 | |
| Ardelyx, INC. | $17.05 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $15.48 | 2020 | |
| Strongbridge US INC. | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoine Dipsia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.